





PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known Application Number 09/889,746 Filing Date December 31, 2001 First Named Inventor Ruelle, Jean-Louis Art Unit 1645 Examiner Name Baskar, Padmavathi Attorney Docket Number BM45352

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
		US-			Br.
		US-		······································	"CCE"
<u> </u>		US-			
		US-			SEP 0 3 20
		US-		'	1FC1, 200
		US-			CENTA.
		US-			1600/20
		US-			1000/29
		US-			
	 	US-			

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Fereign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) MM-DD-YYYY	Or Relevant Figure	Or Relevant Figures Appear	T ⁶	
No.		WO9802547	01-22-1998	Inst. Nat. Sante Rech		
<u> </u>						
						\vdash
						-
		 				
	L			l	L	ــــــــــــــــــــــــــــــــــــــ

Examiner Ωate Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (02-03) Approved for use through 04/30/2003. OMB 0651-0031

	Complete if Known			Under the Pakeryork Reduction Act of 1995, no persons are Substitute for form 1445 PIRADE N			
]	AF-	09/889,746	Application Number		CANDAMA	te toi toini 144	Substitu
h	-CE	December 31, 2001	Filing Date	INFORMATION DISCLOSURE			
PE	SEP	Ruelle, Jean-Louis	First Named Inventor	STATEMENT BY APPLICANT			
<u>.</u>	Ch . " 4 2	1645	Art Unit				
73	CENTED	Baskar, Padmavathi	Examiner Name	(Use as many sheets as necessary)			
7	- 160m	BM45352	Attorney Docket Number	of 2	of	2	Sheet

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium; catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
213		MARTIN D ET AL: "HIGHLY CONSERVED NEISSERIA MENINGITIDIS SURFACE PROTEIN CONFERS PROTECTION AGAINST EXPERIMENTAL INFECTION" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 7,			
	,	LISSOLO L ET AL: "Evaluation of Transferrin-Binding Protein 2 Within" Infection and Immunity, vol. 63, no. 4, March 1995, pages 884-890.			
		SATO Y ET AL: "IMMUNOSTIMULATORY DNA SEQUENCES NECESSARY FOR EFFECTIVE INTRADERMAL GENE IMMUNIZATION" SCIENCE, vol. 273, 19 July 1996 (1996-07-19), pages 352-354			
		CHEE M ET AL: "ACCESSING GENETIC INFORMATION WITH HIGH-DENSITY DNA ARRAYS" SCIENCE, vol. 274, 25 October 1996 (1996-10-25), pages 610-614			
		INFECTION AND IMMUNITY 32, (1981) 592-599.			
		INFECTION AND IMMUNITY 62, (1991) 3017-3021			
		INFECTION AND IMMUNITY 56, (1998) 977-983			
		International Search Report for PCT/EP00/00428 (December 7, 2000)			
		International Preliminary Examination Report for PCT/EP00/00428 (January 15, 2001)			

	U	A
Signature	Date Considered	11/10

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicants.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.